Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M17.0Revenue (TTM) $M--Net Margin (%)--Altman Z-Score-9.1
Enterprise Value $M1.1EPS (TTM) $-1.9Operating Margin %--Piotroski F-Score2
P/E(ttm)--Beneish M-Score-4.0Pre-tax Margin (%)--Higher ROA y-yN
Price/Book1.210-y EBITDA Growth Rate %-51.1Quick Ratio6.4Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-41.1Current Ratio6.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-85.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-96.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M11.8ROIC % (ttm)-1,039,277.8Gross Margin Increase y-yN

Gurus Latest Trades with ABIO

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

ABIO is held by these investors:



ABIO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CONWAY ROBERT EChairman of the Board 2017-07-14Buy10,000$2.49-41.77view
MITCHELL DANIEL JDirector 2017-05-02Buy11,000$2.71-46.49view
Ozeroff Christopher DavidS.V.P., General Counsel 2017-04-04Sell418$2.41-39.83view
Keuer Thomas ACOO 2017-04-04Sell390$2.41-39.83view
BRISTOW MICHAEL RPres. & Chief Executive Offic 2017-04-04Sell720$2.41-39.83view
Selby Brian L.VP, Finance 2017-04-03Sell1,114$2.46-41.06view
CONWAY ROBERT EDirector 2017-03-24Buy25,000$2.59-44.02view
Ozeroff Christopher DavidS.V.P., General Counsel 2017-02-28Sell465$2.61-44.44view
Keuer Thomas ACOO 2017-02-28Sell465$2.61-44.44view
BRISTOW MICHAEL RPres. & Chief Executive Offic 2017-02-28Sell763$2.61-44.44view

Quarterly/Annual Reports about ABIO:

News about ABIO:

Articles On GuruFocus.com
ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Condit Nov 16 2017 
ARCA biopharma to Present at the Sidoti & Company Fall 2017 Conference Sep 21 2017 
ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial Aug 16 2017 
ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phas Aug 09 2017 
ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update Aug 03 2017 
ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis – DSMB Jun 20 2017 
ARCA Biopharma Announces First Quarter 2017 Financial Results and Provides Business Update May 15 2017 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Nov 15 2010 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Aug 10 2010 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) May 10 2010 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK